Rare & Genetic · Clinical trials
Fabry Disease Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About fabry disease — and why its trials are hard
Fabry disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, producing deficient alpha-galactosidase A activity and progressive accumulation of globotriaosylceramide (Gb3) and its deacylated form lyso-Gb3 in vascular endothelium and multiple tissues. Manifestations include neuropathic pain (acroparesthesias), angiokeratomas, hypohidrosis, corneal deposits, and progressive renal, cardiac and cerebrovascular disease that drive morbidity and shortened life expectancy. Classic disease affects males most severely, but heterozygous females can also be significantly affected. Treatment centres on enzyme replacement therapy with agalsidase beta (Fabrazyme) and agalsidase alfa (Replagal, not US-marketed), which clear microvascular Gb3 and aim to slow organ decline. The oral pharmacological chaperone migalastat (Galafold) stabilises endogenous enzyme but only in patients with amenable GLA mutations. Pegunigalsidase alfa (Elfabrio) is a PEGylated ERT with an extended half-life. Endpoints span histological Gb3 clearance, plasma lyso-Gb3, renal function (eGFR slope, proteinuria) and composite clinical events. Early initiation is emphasised to preserve organ function.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Agalsidase beta (Fabrazyme) | 2003 | Enzyme replacement therapy for Fabry disease | Pivotal phase 3 (NEJM 2001) and confirmatory clinical-event trial | Clearance of microvascular endothelial Gb3 deposits (histology); later composite clinical events | Gb3 cleared to normal in 69% of agalsidase beta patients vs 0% placebo (renal/skin/cardiac endothelium) |
| Migalastat (Galafold) | 2018 | Oral chaperone for adults with Fabry disease and amenable GLA mutations | FACETS (phase 3, treatment-naive) | Reduction in kidney interstitial capillary Gb3 inclusions | Significant reduction in kidney GL-3 inclusions vs placebo in amenable-mutation patients; comparable renal stability vs ERT in ATTRACT |
| Pegunigalsidase alfa (Elfabrio) | 2023 | PEGylated enzyme replacement therapy for adults with Fabry disease | BALANCE (phase 3, head-to-head vs agalsidase beta) | Rate of change in eGFR (renal function slope), non-inferiority | Met non-inferiority for eGFR slope vs agalsidase beta with an extended dosing half-life |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in fabry disease development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| FLT190 (Freeline AAV gene therapy) — MARVEL-1 (phase 1/2 Fabry gene therapy) | Program discontinued/deprioritised without reaching registration | Limited and variable enzyme expression relative to targets alongside sponsor restructuring/financing constraints halted development |
Choosing the right endpoint
Primary endpoints that matter in fabry disease trials
- Gb3 / GL-3 clearance — Histological reduction of globotriaosylceramide in kidney, skin and cardiac endothelium; primary endpoint for early ERT and migalastat trials
- Plasma lyso-Gb3 — Circulating biomarker of disease burden and treatment response, useful across ERT, chaperone and gene-therapy programs
- Renal function (eGFR slope, proteinuria) — Rate of decline in estimated GFR and albuminuria/proteinuria; a key long-term clinical endpoint (e.g., BALANCE)
- Composite clinical events — Renal, cardiac and cerebrovascular events plus death; used to demonstrate clinical benefit in confirmatory trials
How iNGENū runs fabry disease trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Fabry Disease clinical trials — FAQs
Who can take migalastat instead of enzyme replacement?
Can Fabry disease affect women?
Does treatment reverse existing organ damage?
Ready to discuss your fabry disease trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal